Ieq Capital LLC Grows Stock Holdings in OPKO Health, Inc. $OPK

Ieq Capital LLC increased its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 417.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 183,363 shares of the biotechnology company’s stock after buying an additional 147,944 shares during the quarter. Ieq Capital LLC’s holdings in OPKO Health were worth $304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in OPK. Millennium Management LLC grew its holdings in shares of OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after buying an additional 1,502,342 shares during the last quarter. Nuveen LLC purchased a new position in shares of OPKO Health during the first quarter worth about $2,286,000. Two Sigma Investments LP grew its holdings in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after buying an additional 949,671 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of OPKO Health by 42.3% during the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 425,484 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of OPKO Health stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the transaction, the chief executive officer owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 49.69% of the company’s stock.

OPKO Health Price Performance

OPK stock opened at $1.35 on Friday. The firm has a 50 day moving average of $1.35 and a 200-day moving average of $1.44. OPKO Health, Inc. has a 12-month low of $1.11 and a 12-month high of $2.04. The company has a current ratio of 3.41, a quick ratio of 3.02 and a debt-to-equity ratio of 0.25. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.40 and a beta of 1.40.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $165.74 million. During the same quarter in the previous year, the business posted ($0.01) earnings per share. OPKO Health’s revenue was down 13.9% on a year-over-year basis. As a group, equities analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Zacks Research raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.